Skip to main content

Table 1 Characteristics of participants by biomarker framework

From: Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study

Characteristics

Stage 0

Stage 1

Stage 2

SNAP

P

n

242

148

70

199

 

Age (years)

60.81 ± 9.95

60.39 ± 10.41

64.19 ± 11.09

64.59 ± 10.28

< 0.001

Gender (F/M)

96 / 146

63 / 85

31 / 39

73 / 126

1.000

Education (years)

9.96 ± 4.39

10.17 ± 4.20

9.24 ± 4.56

9.32 ± 4.37

0.188

APOE ε4 carriers (%)

38 (15.70)

22 (14.86)

18 (25.71)

27 (13.57)

1.000

CM-MMSE score

27.94 ± 2.25

27.92 ± 1.99

27.41 ± 2.18

27.61 ± 2.06

0.155

CSF biomarker

1–42 (pg/ml)

170.41 ± 63.10

103.31 ± 7.26

102.95 ± 6.31

224.78 ± 139.64

< 0.001

1–40 (pg/ml)

5669.91 ± 1855.05

4567.68 ± 1906.91

7379.50 ± 2545.57

8493.87 ± 2982.58

< 0.001

T-tau (pg/ml)

135.72 ± 25.95

124.98 ± 2.55

262.85 ± 104.36

241.30 ± 88.10

< 0.001

P-tau (pg/ml)

33.18 ± 3.85

31.49 ± 3.87

46.13 ± 10.84

46.99 ± 11.37

< 0.001

1–42/Aβ1–40 (Median, IQR)

0.029 (0.024–0.037)

0.024 (0.018–0.032)

0.014 (0.011–0.018)

0.025 (0.18–0.031)

< 0.001

T-tau/Aβ1–42 (Median, IQR)

0.84 (0.69–1.03)

1.20 (1.02–1.36)

2.22 (1.85–3.02)

1.13 (0.90–1.58)

< 0.001

P-tau/Aβ1–42 (Median, IQR)

0.21 (0.17–0.25)

0.31 (0.28–0.33)

0.42 (0.39–0.51)

0.24 (0.19–0.31)

< 0.001

sTREM2 (pg/ml)

18,000.57 ± 6344.52

15,121.87 ± 6396.85

18,282.53 ± 7538.97

20,814.16 ± 6105.39

< 0.001

  1. Categorical variables are reported as numbers and percentages; continuous variables are reported as means ± SDs
  2. Abbreviations: SNAP Suspected non-Alzheimer disease pathology, SD Standard deviations, F Female, M Male, APOE Apolipoprotein E, CM-MMSE China Modified Mini-Mental State Examination, CSF Cerebrospinal fluid; Aβ1–42, amyloid-β1–42; Aβ1–40, amyloid-β1–40; T-tau, total tau; P-tau, phosphorylated tau; sTREM2, soluble TREM2